On November 9, 2020, Vifor Pharma and Angion Biomedica Corp. announced the signing of a licensing agreement for the commercialization of Angion’s ANG-3777 molecule developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). Under the terms of the agreement, Vifor Pharma has been granted an exclusive license for commercializing ANG-3777 nephrology indications worldwide except Greater China. Further, Vifor Pharma has, apart from upfront, clinical and commercial milestone payments as well as royalty payments, agreed to a considerable equity investment in Angion.
Homburger AG acted as legal counsel to Vifor in connection with the legal due diligence review of Angion’s development activities and the drafting, negotiation and final documentation of the license agreement. The Homburger team was led by partner Georg Rauber (IP / IT) and included associates Carola Winzeler (IP / IT), Valentin Fluor (IP / IT, Corporate / M&A) and junior associate Emily Zurfluh.
Contact
Nanding Susso / Marketing / marketing@homburger.ch